MC3R is expressed in the central nervous system (hypothalamus, limbic system) and participates in energy homeostasis regulation, particularly through modulation of circadian food intake rhythm
DL-methionine 3500mg
For hypothyroid patients considering GLP-1, understanding your genetic profile for weight regulation and metabolic efficiency can support a more informed discussion with your provider about whether rapid weight loss might necessitate earlier or more frequent TSH monitoring
Data presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) 2025, a few months back, have provided new insights into the potential role of metformin within a GLP-1 RA-based regimen continuum, with findings that extend beyond glycaemic outcomes into territory that carries greater clinical weight
The goal is physiologic hormone signaling at low circulating levels, potentially sidestepping the nausea, tolerability issues, and chronic dosing burden that cause many patients to discontinue existing GLP-1 therapies
The 2021 STEP 4 trial, published in JAMA, showed that people who continued semaglutide after an initial 20-week run-in kept losing weight, while those who switched to placebo regained nearly 7% of their body weight, confirming that ongoing treatment is key to maintaining results
